Autolus Therapeutics plc delivers a breakthrough CAR-T therapy for B-ALL with strong safety/efficacy. Learn more about AUTL ...

A new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration (FDA) later this month. If ...

At Gilead, we’re advancing new ways to help end the HIV epidemic by delivering innovative therapies to those who need them ...

The Wall Street Journal reports on the expected FDA approval of lenacapavir and what it might mean for Gilead's future in the market. Other coverage of science and research-related news is on a ...

Avenzo Therapeutics has commenced the open-label Phase I/II trial of its CDK4 selective inhibitor, AVZO-023, for breast ...

Total gross proceeds of up to $150.0 million before the end of 2026 if all Series B warrants and Series C warrants are ...

Gilead Sciences Inc. closed 7.92% below its 52-week high of $119.96, which the company achieved on March 10th.

Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S.

Jefferies analyst Michael Yee reaffirmed a Buy rating on Gilead Sciences Inc. (NASDAQ:GILD), maintaining his price target at ...

Impax Asset Management, an investment management company, released its “Impax US Sustainable Economy Fund” first quarter 2025 ...

It trades at 13.3 times forward earnings—below the industry average of 14, as measured by the NYSE Arca Pharmaceutical Index, ...

The shift toward universal screening for diseases like hepatitis C, hepatitis B, and HIV removes part of the burden of ...